Navigation Links
FavId in Medical News

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

New Product Name Also Unveiled in Ongoing Preparation for Commercial Launch SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that new data, including f...
FavId in Medical Technology

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European Hematology Association SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced interim data from a Phase 2 clinical trial...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...domized, double-blind, placebo controlled trial of favid following Rituxan(R) treatment in patients with fo... patients were randomly assigned to receive either favid plus Leukine(R) (sargramostim, GM-CSF) or placebo ...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ing them potentially more active as well." About favid favid is a patient-specific, Id/KLH active immunotherapy...nrollment in its pivotal Phase 3 clinical trial of favid following Rituxan(R) induction therapy in patients...
FavId in Biological Technology

Favrille Announces $21.1 Million Registered Direct Offering

...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas... development, testing, manufacturing and marketing favid or Favrille's other product candidates; delays in ...can serve as the basis for accelerated approval of favid and whether it will receive expedited review as a ...

Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007

...eases of the immune system. The Company's lead product candidate, FavId(R), is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clin...

Favrille to Present at BIO InvestorForum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at Bear Stearns Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...
Other Tags
(Date:5/27/2015)... One of America's most cherished actors, James Earl ... that takes a look at the topic of atrial ... abnormal heart rhythm. Those who suffer from atrial fibrillation ... too quickly. , This new segment will take a ... to inform viewers about possible signs that commonly indicate ...
(Date:5/27/2015)... 27, 2015 The Academy of Oncology ... Coast Regional Meeting in Seattle. This intimate gathering, held ... 200 navigation and oncology professionals from west of the ... , “One of the most important things that an ... their needs and do the best it can to ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
(Date:5/26/2015)... Readers who struggle with memory , ... Chester Litvin ’s new book, “ Introduction to ... Trafford Publishing). , Litvin, who is a clinical psychologist, ... This book will guide readers through a series of ... cells . He shares his patented process for reviving ...
(Date:5/26/2015)... Liverpool, Ohio (PRWEB) May 26, 2015 Mr. ... role since 2010, will start working together this week to ... an accomplished career in healthcare executive leadership and strategy. ... CEO prior to the hiring of Mr. Cochran. The Board ... skills will complement the improvement strategies implemented over the past ...
Breaking Medicine News(10 mins):Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 2Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 3Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
Other Contents